Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Randomized Controlled Pharmacist Intervention Study to Reduce Drug-related Problems and Readmissions Among Old People With Dementia

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2014 by Umeå University
Information provided by (Responsible Party):
Hugo Lovheim, Umeå University Identifier:
First received: January 3, 2012
Last updated: December 10, 2014
Last verified: December 2014

The aim of this randomized controlled study is to investigate if medication reviews performed by a clinical pharmacist as part of a ward team can reduce drug related problems and reduce readmissions to hospital among elderly patients (≥65 years) with dementia and cognitive failure.

Four hundred and sixty patients will be recruited and randomized to control (usual care) and intervention group (enhanced service in which a pharmacist is part of the health care team).

Six months after the last patient of the 460 has been discharged the study will be closed. Data about the number of readmissions and visits to the emergency room will be collected during the six-month follow-up and also, the costs associated with each visit or admission. Time until institutionalization will be compared between intervention group and control group.

Condition Intervention
Cognitive Impairment
Other: Medication review

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Official Title: A Randomized Controlled Pharmacist Intervention Study to Reduce Drug-related Problems and Readmissions Among Old People With Dementia

Resource links provided by NLM:

Further study details as provided by Umeå University:

Primary Outcome Measures:
  • Frequency of drug related readmissions [ Time Frame: Six months follow-up ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Cost for visits for readmissions and to the Emergency Department compared between patients in the control group and intervention group. [ Time Frame: Six months follow-up ] [ Designated as safety issue: No ]
  • Time until institutionalization after discharge compared between control group and intervention group. [ Time Frame: Six months follow-up ] [ Designated as safety issue: No ]
  • Frequency of hospital visits (readmissions and emergency department) during the 6-month follow-up. [ Time Frame: Six months follow-up ] [ Designated as safety issue: No ]
  • Time from discharge to readmission [ Time Frame: Six months follow-up ] [ Designated as safety issue: No ]
  • Adherence to the quality indicators published by the Swedish National Board of Health and Welfare [ Time Frame: Six months follow-up ] [ Designated as safety issue: No ]

Estimated Enrollment: 460
Study Start Date: January 2012
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Medication review Other: Medication review

In the intervention, the pharmacist will evaluate:

  • Is there an indication for the drug?
  • Has the drug desired effect?
  • Is the dose correct and dosing scheme correct?
  • Side effects, contraindications, inappropriate drugs
  • Interactions
  • Treatment time
  • Cost effectiveness
  • Adherence to recommendation list
  • Problems with handling the drugs (for example crushing of the tablets)
  • Untreated indication
  • Double medications
  • Administration of drugs
No Intervention: Usual care


Ages Eligible for Study:   65 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with dementia or cognitive impairment
  • Patients ≥ 65 years

Exclusion Criteria:

  • Patients previously admitted to the study wards during the study period
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01504672

Contact: Hugo Lövheim, MD, PhD 0046702979499

County hospital of Skellefteå Recruiting
Skellefteå, Sweden, 931 86
Contact: Hugo Lövheim, PhD    0046702979499   
Contact: Jeanette Jonsson    0046910-71 62 07   
Principal Investigator: Hugo Lövheim, MD, PhD         
Sub-Investigator: Maria Gustafsson         
Umeå University Hospital Recruiting
Umeå, Sweden, 901 85
Contact: Hugo Lövheim, PhD    0046702979499   
Contact: Maria Gustafsson    00467853562   
Principal Investigator: Hugo Lövheim, MD, PhD         
Sub-Investigator: Maria Gustafsson         
Sponsors and Collaborators
Umeå University
  More Information

No publications provided

Responsible Party: Hugo Lovheim, Principal Investigator, Umeå University Identifier: NCT01504672     History of Changes
Other Study ID Numbers: UmU-2011-148-31M
Study First Received: January 3, 2012
Last Updated: December 10, 2014
Health Authority: Sweden: Regional Ethical Review Board

Keywords provided by Umeå University:
Drug related problems processed this record on February 27, 2015